Breast Cancer

Phase 2 data indicate that CD8 status may serve as a biomarker for predicting treatment efficacy with tislelizumab-based treatment in TNBC.

The first stage of a phase 2 trial evaluating neoadjuvant SHR-A1811 in breast cancer meets its primary end point of ORR.

LumiSystem prompted the removal of a median of 10.5cc extra tumor margin tissue in patients with breast cancer and did not significantly affect satisfaction outcomes.

Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.

The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.

Nab-paclitaxel elicited a pathologic complete response rate of 66.3% compared with 57.6% with docetaxel plus carboplatin, the phase 3 HELEN-006 trial found.

SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.

Patients with ER+/HER2– advanced breast cancer saw positive efficacy and safety data following treatment from the SERENA-1 trial.

Ultra-sensitive ctDNA testing identified ctDNA at baseline in patients with HR–positive breast cancer, results from the PELOPS trial showed.

Atezolizumab with chemotherapy did not yield a significant increase to event-free survival compared with placebo with chemotherapy, 85.2% vs 81.9%, respectively.

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

The phase 3 CamRelief study reported a pathologic complete response rate of 56.8% for camrelizumab plus chemo compared with 44.7% for chemo alone.

Data from the RIGHT Choice study showed that ribociclib/ET yielded efficacy benefits for luminal B/HER2E breast cancer vs combination chemotherapy.

Palbociclib combination therapy elicited a progression-free survival of 44.3 months compared with the 29.1 months of SOC in HR+, HER2+ breast cancer.

Data from the EMBER-3 trial showed improved progression-free survival with imlunestrant with or without abemaciclib vs SOC in ER+/HER2– breast cancer.

Elascestrant with abemaciclib elicited an overall response rate of 18% in ER+/HER2– Breast Cancer, results from the 2 trials show.

When compared with endocrine therapy, radiation therapy improved quality of life and adverse effects data, the phase 3 EUROPA study showed.

Analysis of NRG/RTOG 9804 and E5194 trials found tamoxifen significantly reduced invasive ipsilateral breast recurrence in patients with “good risk” DCIS treated without RT.

Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.

Real-world data from the P-VERIFY study didn’t find any notable OS improvements between multiple CDK4/6 inhibitor combos in metastatic breast cancer.

During an FDA Special Session, field experts talked about the NATALEE trial and further information gathering on adjuvant ribociclib in breast cancer.

For patients with HR–positive/HER2-negative breast cancer, neoadjuvant patritumab deruxtecan with or without letrozole showed antitumor activity.

Data show no significant differences in pCR rates across treatment arms in the phase 2 FASCINATE-N trial.

Six-year data from the OlympiA trial support olaparib as a standard of care in BRCA-mutated, high-risk, HER2-negative primary breast cancer.

Time to next treatment was slightly higher with elacestrant for patients with HR+/HER2–, ESR1-mutant breast cancer vs PFS in a phase 3 trial.

For patients with hormone receptor-positive and HER2-low breast cancer, T-DXd elicited higher levels of PFS despite time to progression and disease burden.

Findings from a multi-institutional study show an increased risk of developing high-grade immune-related AEs among select older patients with early-stage breast cancer.

According to a retrospective study, patients with the BRCA gene who underwent risk-reducing mastectomy/salpingo-oophorectomy had improved survival outcomes.